| Status | Suspended |
| Decision | Selected |
| Process | STA pre-2018 |
| Referral date | 01 November 2010 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 May 2011 |
The Institute has been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for naproxcinod. Further information NICE has therefore decided to suspend this appraisal on its current work programme for the time being. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual